Great Ormond Street Hospital (GOSH)’s mission is to provide world-class clinical care and training, pioneering new research and treatments, in partnership with others, for the benefit of children in the UK and worldwide.
Across our departments and directorates we have a shared vision to produce world leading translational and patient-orientated research. We are always aspiring to develop new research and treatments across the breadth of paediatric specialities. GOSH is fully committed to conducting high quality research in collaboration with our various academic and industry partners.
At GOSH, our research teams are consistently amongst the best in the world in their disciplines. Our highly skilled researchers, with the support of the entire Trust’s workforce, are using cutting-edge techniques and equipment to:
- Develop novel and improved diagnostics for our patients and the wider population.
- Pioneering innovative treatments and therapies for our patients.
- Performing high quality clinical trials of academic and industry-led medicines and therapeutics.
- Understanding and preventing the development and progression of childhood illnesses.
- Evaluating, at a multi-disciplinary level, the impact and progression of disease and our interventions
and treatments, in partnership with others, for the benefit of children in the UK and worldwide.
With its broad range of clinical specialties, GOSH is in a unique position to undertake research into the most complex and rare childhood diseases. At any one time, there are several hundred active research projects ranging from observational studies to clinical trials of medicinal products. In collaboration with our colleagues at the UCL Great Ormond Street Institute of Child Health (GOS ICH), the Trust is currently involved with over 60 individual research groups dedicated to rare diseases.
GOSH is also the site of a National Institute for Health Research (NIHR) Biomedical Research Centre (BRC). GOSH and GOS ICH were first awarded NIHR BRC status in 2007, and, in 2016, we secured £37 million for our third term, running until the end of 2022. Funding enables basic scientific discoveries made in laboratories to be translated into ‘first in man’ or ‘first in child’ clinical studies. Find out more about our NIHR GOSH BRC here.